Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension

Journal of Clinical Hypertension

Volumn 11, Issue 9, 2009, Pages 475-482

  Chrysant, Steven G ^a   Oparil, Suzanne ^b   Melino, Michael ^c   Karki, Sulekha ^c   Lee, James ^c   Heyrman, Reinilde ^c  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c DAIICHI SANKYO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN; PLACEBO; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; HUMAN; HYPERTENSION; HYPOTENSION; LIMB PAIN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; THORAX PAIN; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; AGED; DRUG COMBINATION; DRUG EFFECTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTOR; TIME;

AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIURETICS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; TETRAZOLES; TIME FACTORS;

EID: 70349973807     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2009.00159.x     Document Type: Article

References (27)

1. Bestehorn K, Wahle K, Kirch W. Stroke risk screening of adults with hypertension: prospective cross-sectional study in primary care. Clin Drug Investig 2008, 28(5):281-289.
2. Kearney PM, Whelton M, Reynolds K. Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365(9455):217-223.
3. Lloyd-Jones D, Adams R, Carnethon M. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009, 119(3):480-486.
4. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003, 362(9395):1527-1535.
5. Chobanian AV, Bakris GL, Black HR. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42(6):1206-1252.
6. Mancia G, De Backer G, Dominiczak A. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25(6):1105-1187.
7. Lewington S, Clarke R, Qizilbash N. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360(9349):1903-1913.
8. Bakris GL. Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens (Greenwich) 2008, 10(1 Suppl 1):27-32.
9. Chrysant SG. Using fixed-dose combination therapies to achieve blood pressure goals. Clin Drug Investig 2008, 28(11):713-734.
10. Law MR, Wald NJ, Morris JK. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003, 326(7404):1427.
11. Epstein BJ, Vogel K, Palmer BF. Dihydropyridine calcium channel antagonists in the management of hypertension. Drugs 2007, 67(9):1309-1327.
12. Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs 2008, 68(9):1239-1272.
13. Chrysant S, Melino M, Karki S. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008, 30(4):587-604.
14. Barrios V, Boccanelli A, Ewald S. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study. Clin Drug Investig 2007, 27(8):545-558.
15. Izzo JL, Neutel JM, Silfani T. Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J Clin Hypertens (Greenwich). 2007, 9(1):36-44.
16. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006, 19(11):1190-1196.
17. Elliott W. What factors contribute to the inadequate control of elevated blood pressure?. J Clin Hypertens (Greenwich) 2008, 10(1 Suppl 1):20-26.
18. Gregoire J, Moisan J, Guibert R. Predictors of self-reported noncompliance with antihypertensive drug treatment: a prospective cohort study. Can J Cardiol 2006, 22(4):323-329.
19. Weir MR. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens (Greenwich) 2003, 5(5):330-335.
20. Blackshear JL, Schwartz GL. Step care therapy for hypertension in diabetic patients. Mayo Clin Proc 2001, 76(12):1266-1274.
21. Ofili EO. Dispelling the myth of " aggressive" antihypertensive therapy. J Clin Hypertens (Greenwich) 2006, 8(1 Suppl 1):4-11.
22. Okonofua EC, Simpson KN, Jesri A. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals. Hypertension 2006, 47(3):345-351.
23. Phillips LS, Branch WT, Cook CB. Clinical inertia. Ann Intern Med 2001, 135(9):825-834.
24. Cushman WC, Ford CE, Cutler JA. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002, 4(6):393-404.
25. Kerr EA, Zikmund-Fisher BJ, Klamerus ML. The role of clinical uncertainty in treatment decisions for diabetic patients with uncontrolled blood pressure. Ann Intern Med 2008, 148(10):717-727.
26. Phillips LS, Twombly JG. It's time to overcome clinical inertia. Ann Intern Med 2008, 148(10):783-785.
27. Jamerson K, Weber MA, Bakris GL. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008, 359(23):2417-2428.